Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs.
Can J Vet Res. 2018 Jul;82(3):178-183
Authors: Bartner LR, McGrath S, Rao S, Hyatt LK, Wittenburg LA
The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.
PMID: 30026641 [PubMed – in process]
Source: Estudios sobre Cannabidiol (CBD)